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Abstract
Background: An increasing number of studies support the presence of stem-like cells in human malignancies.
These cells are primarily responsible for tumor initiation and thus considered as a potential target to eradicate
tumors. CD133 has been identified as an important cell surface marker to enrich the stem-like population in
various human tumors. To reveal the molecular machinery underlying the stem-like features in tumor cells, we
analyzed a promoter of CD133 gene using human colon carcinoma Caco-2 and synovial sarcoma Fuji cells, which
endogenously express CD133 gene.
Results: A reporter analysis revealed that P5 promoter, located far upstream in a human CD133 gene locus,
exhibits the highest activity among the five putative promoters (P1 to P5). Deletion and mutation analysis
identified two ETS binding sites in the P5 region as being essential for its promoter activity. Electrophoretic
mobility shift assays demonstrated the specific binding between nuclear factors and the ETS binding sequence.
Overexpression of dominant-negative forms of Ets2 and Elk1 resulted in the significant decrease of P5 activity.
Furthermore, treatment of Fuji cells with a specific MEK/ERK inhibitor, U0126, also markedly decreased CD133
expression, but there was no significant effect in Caco-2 cells, suggesting cell type-specific regulation of CD133
expression. Instead, the side population, another hallmark of TSLCs, was dramatically diminished in Caco-2 cells by
U0126. Finally, Ras-mediated oncogenic transformation in normal human astrocytes conferred the stem-like
capability to form neurosphere-like colonies with the increase of CD133 mRNA expression.
Conclusions: In conclusion, the Ras/ERK pathway at least in part contributes to the maintenance and the
acquisition of stem-like hallmarks, although the extent of its contribution is varied in a cell type-specific manner.
These findings could help our comprehensive understanding of tumor stemness, and also improve the
development of eradicative therapies against human malignancies.
Background
The tumors contain a sub-population of specific cells
which are primarily involved in tumor formation and
maintenance [1]. Those cells are referred as tumor
stem-like cells (TSLCs), and CD133 (also known as pro-
minin-1 or AC133) has been considered as an important
marker to enrich the stem-like population in tumors of
various tissues, including those of the brain [2], prostate
[3], pancreas [4], liver [5], colon [6,7], and skin for
melanoma [8]. CD133+ tumor cells possess the ability to
self-renew without limit and to generate the majority of
differentiated progenies [9]. They are also more resistant
to chemo- and radiotherapy when compared to CD133-
tumor cells, resulting in tumor progression and recur-
rence, and thus are considered as a potential therapeutic
target to eradicate tumors [10-12]. However, the mole-
cular mechanisms underlying this tumor stemness are
still under investigation.
CD133 is a cellular surface glycoprotein containing
five transmembrane regions and two glycosylated extra-
cellular loops and has a molecular weight of 97-120
kDa. It was identified as a specific antigen for human
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hematopoietic stem cells [13], and is currently used for
the isolation of stem-like cells from numerous tissues
[13-20]. Although little is known about the biological
function of CD133, recent studies have shown that pro-
minin-1 null mice were born and aged normally [21],
but resulted in progressive degeneration of mature
photoreceptors with complete loss of vision after post-
natal day 15 [22]. Transcription of CD133 gene is
known to be controlled by alternative five promoters
(P1, P2, P3, P4, and P5), and exon 1 produces different
spliced 5’-UTRs, which are expressed in a tissue-specific
manner [23]. We previously showed that the methyla-
tion status of CpG sites residing in P1 and P2 regions is
inversely correlated with the expression levels of CD133
mRNA in human glioma tissues [24]; however, any
molecules involved in the transcriptional regulation of
CD133 gene are still unknown.
The E26 transformation-specific (ETS) family consists of
over 35 Ets genes that can be structurally categorized into
11 subfamilies in humans [25]. Individual Ets genes share
a highly conserved DNA-binding domain composed of
about 85 amino acid residues referred to as the ETS
domain, which recognizes purine-rich GGA(A/T) (ETS
binding site; EBS). Several Ets factors have been shown to
be nuclear targets for the activation of the Ras/Raf/MEK/
ERK signaling pathway and are involved in various biologi-
cal processes, including cell proliferation, apoptosis, differ-
entiation, hematopoiesis, tissue remodeling, angiogenesis,
metastasis, and oncogenic transformation [25]. The altered
expression levels of Ets or chromosomal amplification,
deletion, and translocation are known to cause human leu-
kemia or specific types of solid tumors [26].
To investigate the molecular mechanism underlying
stem-like features in human tumors, we characterized a
promoter region of human CD133 gene by using human
carcinoma and sarcoma cell lines. We found that the
ERK pathway is involved in the expression of CD133,
and its inhibition was also shown to decrease the fre-
quency of side population (SP), another hallmark of
stem-like cells. Finally, it was revealed that Ras-mediated
transformed astrocytes have an ability to form greater
colonies in the neural stem cell culture condition,
together with the increased CD133 mRNA expression.
Thus, our finding could provide important insights into
the molecular basis of tumor stemness.
Methods
Cell culture, reagents, and transfection
The human colon carcinoma cell line Caco-2 and syno-
vial sarcoma cell line Fuji were cultured in DMEM sup-
plemented with 20% and 10% fetal bovine serum (FBS),
respectively. The immortalized normal human astrocytes
NHA/TS and Ras-transformed NHA/TSR cells were
previously established [27]. Cells were treated with the
MEK inhibitor U0126 (Cell Signaling Technologies, Bev-
erly, MA, USA) at 20 μM for 72 hours with renewal of
media every 24 hours. Fugene HD transfection reagent
(Roche, Indianapolis, USA) was used for transfection.
For primary neurosphere formation, NHA/TS and
NHA/TSR cells (1000 cells/3.5 cm dish) were cultured
in neural stem cell (NSC) medium (DMEM/F12 con-
taining 20 ng/ml EGF, 20 ng/ml bFGF, 1× B27, and 1%
penicillin and streptomycin) for 2 weeks as described
previously with minor modification [28]. After 2 weeks
of culture, TSR spheres were collected, enzymatically
dissociated by Trypsin-EDTA and reseeded at a density
of 1000 cells/3.5 cm dish) for secondary sphere forma-
tion. For clonal culture, single NHA/TS or NHA/TSR
cell was transferred into 48-well plates containing NSC
medium using cell sorter. After 2 weeks, each well was
manually screened for a colony using phase contrast
microscopy. Thereafter, each individual primary TSR
sphere was dissociated and reseeded (1000 cells/3.5cm
dish) again for secondary sphere formation. For reactiva-
tion of CD133 expression, cells were treated with 5 μM
5-Aza-2-deoxycitidine (5-Aza-dC; Sigma, St. Louis, MO,
USA) for the initial 48 hours, and then in combination
with 500nM Trichostatine A (TSA; Sigma) for an addi-
tional 24 hours.
Plasmids
pCR3.1-Uni-CD133 expression plasmid was kindly pro-
vided by Dr. Denis Corbeil [29]. pGL3 enh-P1, P2, and P3
were previously established [24]. To generate pGL3enh-P4
and P5 reporter gene constructs, P4 and P5 regions of
human CD133 gene were amplified by PCR using genomic
DNA isolated from human normal peripheral blood
monocytes. Oligonucleotide primers were designed on the
basis of DNA sequences {GenBank: AY438641 for P4 and
GenBank: AY438640 for P5}. The PCR products were gel-
purified, cloned into pCR-Blunt II-TOPO vector (Invitro-
gen, Carlsbad, CA, USA) verifying sequences, and
subcloned into the pGL3 enhancer luciferase reporter
plasmid (pGL3enh) (Promega, Madison, WI, USA). The
reporter plasmids driven by P5 or its deleted forms
(pGL3enh-P5-1068, -768, -368, -98, -25) and mutant plas-
mids of P5 for ETS binding core sequence (GGAA) such
as pGL3enh-P5-98mEBS#1, pGL3enh-P5-98mEBS #2, and
pGL3enh-P5-98mEBS #1#2, were constructed by PCR-
based methods. The cDNA encoding the dominant nega-
tive forms of Ets2 (corresponding to amino acid residues
332-469) and Elk1 (corresponding to amino acid residues
1-168), which lack the transcriptional activation domain,
were amplified from human brain cDNA and inserted into
XhoI and NotI sites of the pCXN2-Flag expression plas-
mid [30]. For retrovirus-mediated transfer of Ets2 and
CD133 genes into NHA/TS cells, the each cDNA ampli-
fied from human brain cDNA and pCR3.1-Uni-CD133
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vector was subcloned into pCX4pur retroviral vector
kindly provided by Dr. Tsuyoshi Akagi [31].
RNA extraction and semiquantitative RT-PCR
RNA was isolated with TRI Reagent (Sigma) according
to the manufacturer’s instructions. After oligo(dT)-
primed reverse transcription of 4 μg of total RNA was
conducted, the resulting single-stranded cDNA was
amplified by PCR using KOD-Plus DNA polymerase
(TOYOBO, Osaka, Japan). The specific primers are
listed in Additional file 1, Figure S1.
Immunoblotting
Immunoblotting was performed as described previously
[32]. Briefly, cells were lysed and protein concentration
of lysates was determined by Protein Assay reagent
(Bio-Rad, Richmond, CA, USA). Thirty μg of proteins
were separated by SDS-PAGE and transferred to a
polyvinylidene difluoride filter, which was subsequently
incubated with Tris-HCl-based buffer (pH 7.4)
containing 5% dried nonfat milk for 1 hour at room
temperature (RT). Filters were probed with mouse
monoclonal antibodies to CD133 (1: 200; Miltenyi
Biotec, Auburn, CA, USA), Flag M2 (1: 1000; Sigma),
and Actin (1: 2500; Chemicon, Temecula, CA, USA),
or rabbit polyclonal antibodies to ERK1 (1: 200; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and phos-
pho-p44/p42 MAPK (1: 1000; Cell Signaling). Bound
antibodies were detected with peroxidase-labeled goat
antibody to mouse IgG or goat antibody to rabbit IgG
and visualized by enhanced chemiluminescence
reagents (Amersham Pharmacia Biotech, Freiburg,
Germany).
Luciferase reporter assay
Dual-luciferase reporter assay was performed as
described previously [33]. Briefly, cells plated on 24-well
plates were transiently transfected with both of CD133
promoter-firefly luciferase plasmids and internal control
plasmid as pRL-TK (Promega) encoding Renilla lucifer-
ase for monitoring transfection efficiency. After 48
hours, luciferase activity was measured, and the ratio of
firefly activity normalized with the Renilla activity was
calculated for each transfection. In the experiments
using Ets dominant negative constructs and U0126, sin-
gle reporter assay system was conducted to exclude the
possibility that pRL-TK control vector could be affected
by the change of Ets expression, by normalizing firefly
activity to protein concentration of cell lysate for each
transfection or treatment.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described previously
[33]. All synthetic oligonucleotides were annealed and
end-labeled by T4 polynucleotide kinase (Promega) with
[g-32P]ATP (Amersham). The following 25 bp oligonu-
cleotides (double strand DNA) were used for experiments:
EBS1, 5’-ATCAGGCAGGAAGGGTAGAATGCTG-3’
(position -62 to -38 of CD133 P5 promoter); mEBS1, 5’-
ATCAGGCATTAAGGGTAGAATGCTG-3’ (position -62
to -38 of CD133 P5 promoter with mutated Ets site);
EBS2, 5’-TGCTGGGACAGGAAGTAGCTTGGAG-3’
(position -42 to -18 of CD133 P5 promoter); mEBS2, 5’-
TGCTGGGACATTAAGTAGCTTGGAG-3’ (position -42
to -18 of CD133 P5 promoter with mutated Ets site);
Cons. EBS, 5’-GGGCTGCTTGAGGAAGTATAAGAAT-
3’ (Ets responsive element of the human erbB2 promoter
[34]); and -25/-1, 5’-GCTTGGAGGTGGGCCT-
TAGGCTGGT-3’ (position -25 to -10 of the CD133 P5
promoter without Ets site). Nuclear extracts containing
10 μg of proteins were incubated for 20 minutes at RT
with ~ 100,000 cpm of the labeled probe in a final volume
of 20 μl of 10 mM Tris-HCl (pH 7.5) buffer containing
50mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 5% gly-
cerol, and 1 μg poly(dI-dC)poly(dI-dC). For competition
experiments, 50-fold molar excess of the cold oligonucleo-
tide was added to the nuclear extracts 10 minutes prior to
addition of the labeled probe. The reacted probes were
subjected to electrophoresis (250 V for 90 minutes at 4°C)
on a non-denaturing, 5% polyacrylamide gel containing
1xTGE (25 mM Tris-HCl, 190 mM glycine, 1 mM EGTA)
buffer.
Magnetic and fluorescence activated cell sorting
For enrichment of CD133-expressing cells, Fuji cells
were subjected to immunomagnetic separation using a
magnetic activated cell sorting (MACS) CD133 Cell Iso-
lation Kit (Miltenyi Biotec), according to the manufac-
turer’s protocol. Briefly, dissociated cells incubated for
30 minutes at 37°C were labeled with CD133/1 Micro
Beads. After washing, labeled cells were loaded onto a
column installed in a magnetic field. Trapped cells were
collected as CD133high fraction after the column was
removed from the magnet. The collected cells were
applied to a second column and the purification step
was repeated. The flow-through of the MACS column is
used as CD133low fraction. To check the expression of
CD133, cells were stained with phycoerythrin (PE)-con-
jugated monoclonal antibodies for human CD133
(CD133/2-PE, Miltenyi Biotec) or isotype control anti-
body IgG2b-PE (Miltenyi Biotec) (1:10 diluted 4°C for
10 minutes in the dark). After washing, the labeled cells
were analyzed by a BD FACS Aria flow cytometer (BD
Biosciences, San Jose, CA, USA).
Side population (SP) analysis
To measure the proportion of SP cells, cells were
stained with Hoechst 33342 dye (Molecular Probes,
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Eugene, OR, USA) as previously described [35]. Briefly,
cells (1 × 106 cells/ml) were resuspended in pre-warmed
DMEM with 2% FBS. Hoechst 33342 was added at a
final concentration of 5 μg/ml in the presence or
absence of 50 μM verapamil (Sigma) and the cells were
incubated at 37°C for 90 minutes. After incubation, cells
were washed and resuspended in cold DMEM with 2%
FBS. Propidium iodide (Molecular Probes) at a final
concentration of 1 μg/ml was added to discriminate
dead cells. Analyses were performed on a BD FACS
Aria SORP flow cytometer (BD Biosciences). The
Hoechst dye was excited with the UV laser and its fluor-
escence was measured with a 405/20 nm band pass filter
(Hoechst blue) and a 670 nm long pass filter (Hoechst
red). Cells were pre-gated through FSC-W vs. FSC-H,
and SSC-W vs. SSC-H dot plot to exclude doublet cells.
Soft-agar colony formation assay
Colony formation assay was performed as described pre-
viously [33]. Briefly, cells (4 × 104 cells per 6cm-dish)
were suspended in 0.36% noble agar, and plated on 0.6%
bacto agar. Colonies were stained with dimethylthiazol-
diphenyltetrazolium (MTT), and photographed by Fuji
LAS-1000 imaging system. Colony numbers were calcu-
lated by using Multigauge Colony Count Software.
In vivo tumor formation analysis
Animal procedures were performed according to a pro-
tocol approved by the institutional Animal Care and
Use Committee at Hokkaido University Graduate School
of Medicine. 5 × 106 cells were mixed with matrigel (BD
Biosciences) and subcutaneously injected into female
nonobese diabetic/severe combined immunodeficiency
(NOD/SCID) mice at 6-8 weeks of age. Tumor forma-
tion was assessed at 6 weeks after inoculation.
Statistical analysis and computer analysis
Comparison between experimental groups was made by
Student’s t-test. p < 0.05 was considered significant. The
TFSEARCH program http://www.cbrc.jp/research/db/
TFSEARCHJ.html was used for analysis of possible bind-
ing sites of transcription factors.
Results
P5 exhibits the highest activity among the five putative
promoters of CD133 gene
To analyze the transcriptional machinery of CD133
gene, we used a human colon carcinoma cell line Caco-
2 and a human synovial sarcoma cell line Fuji, because
both cell lines express abundant CD133 transcripts and
proteins, and also CD133+ Caco-2 cells are reported to
be able to generate tumors following transplantation in
mice, whereas CD133- cells are not [36]. Our previous
studies showed that Caco-2 expresses the transcripts
containing all variants of exon 1, and Fuji expresses only
exons 1A, 1B, 1C, and 1E (Figure 1D). Immunoblotting
and RT-PCR analysis confirmed that the expression
levels of CD133 mRNA and protein in Caco-2 cells are
higher than those in Fuji cells (Figure 1A, Figure 1B).
FACS analysis using anti-CD133 antibody revealed that
both cell lines exhibit the cellular heterogeneity for
CD133 expression (Figure 1C), as the CD133 positive
fraction is 88.9% and 18.2% in Caco2 and Fuji cells,
respectively. Luciferase assay demonstrated a remarkable
activation of P5 (pGL3enh-P5-1368) and a modest acti-
vation of P1 (pGL3enh-P1-1182), and no significant
enhancement of P2 (pGL3enh-P2-253) and P3
(pGL3enh-P3-199) was detected in both cells (Figure
1E). A modest activation of P4 (pGL3enh-P4-1451) was
observed only in Caco-2 cells, which probably contri-
butes to the expression of exon 1D-containing
transcripts.
Ets binding motifs are required for CD133 P5 activity
To determine the minimal region essential for P5 pro-
moter activity, we generated a series of deletion mutants
of P5 promoter (pGL3enh-P5-1068, -768, -368, -98, and
-25) and found that deletion to -98 holds a similar luci-
ferase activity to the full-length promoter (pGL3enh-P5),
but the further deletion to -25 leads to a significant
reduction of activity (Figure 2A), suggesting that the
region between -98 and -25 contains minimal elements
required for CD133 transcription through P5 promoter.
The region between -98 to -25 contains two consensus
binding motifs of Ets family proteins (G/C)(A/C)
GGAAG(G/T) (Additional file 1, Figure S2A) [37]. To
determine whether these Ets motifs are necessary for P5
activity, we introduced a substitutional mutation altering
two nucleotides of Ets core sequence GGAA to TTAA,
into each or both of the Ets binding sites, designated as
pGL3enh-P5-98mEBS#1, #2, and #1#2. Introduction of
the mutation at EBS#1 moderately decreased P5 promo-
ter activity and the mutation at EBS#2 remarkably
decreased the activity (Figure 2B). These results indi-
cated that the two Ets binding motifs are required for
the P5 activity, and that in particular, mutation of
EBS#2 resulted in the greatest reduction of P5 activity.
Specific binding of nuclear factors to an Ets motif #2 in
CD133 P5
Next, to investigate the specific transcription factor
which binds to EBS between -98 to -25 of P5, EMSA
was performed using nuclear proteins extracted from
Caco-2 and Fuji cells. A 25-bp double-stranded oli-
goDNA containing putative Ets binding sites was
synthesized as probes or as unlabeled competitors
(Additional file 1, Figure S2B). As shown in Figure 2C,
an EBS2 probe, which was designed to span the -42/-18
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Figure 1 Expression and promoter activities of CD133 gene in human colon carcinoma Caco-2 and synovial sarcoma Fuji cell lines.
A, Immunoblot analysis of CD133 protein in Caco-2 and Fuji cell lines. Human kidney cell line 293T and 293T transfected with pCR3.1-Uni-CD133
(293T/C) was used as a negative and a positive control, respectively. Actin is an internal control. B, Semiquantitative RT-PCR analysis of CD133
mRNA in Caco-2 and Fuji cell lines. cDNA from 293T and 100 ng of pCR3.1-Uni-CD133 plasmid (pCD133) were used as a negative and a positive
control, respectively. The number of PCR cycles was at 32 for CD133. GAPDH is an internal control. C, FACS analysis of Caco-2 and Fuji lines with
CD133/2-PE antibody. Numbers indicate the percentage of CD133-positive cells in the total population. The bold line represents a staining with
CD133-PE antibody, and the dotted line represents the isotype control antibody. D, Schematic representation of the position of five CD133
promoters (P1 to P5) and exon1s (A to E). Gray boxes represent five first exons starting from the transcriptional start positions. Exons 1C2, 1D4,
and 1E5 were identified in our previous study [24]. E, Promoter activity of P1, P2, P3, P4, and P5 in Caco-2 and Fuji cell lines. Left panel,
schematic representation of luciferase reporter plasmids containing five CD133 promoters. +1 indicates the transcription start position of each
exon1s. Right panel, luciferase activities of Caco-2 and Fuji cells transfected with five indicated reporters. Data are means ± s.d. of values from
three independent experiments.
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Figure 2 Identification of Ets binding motifs essential for CD133 P5 activity. A, Deletion analysis of the promoter activity of CD133 P5. Left
panel, schematic representation of luciferase reporter constructs containing the deleted sequence of P5 region. +1 indicates the transcription
start position of exon1E1. Right panel, luciferase activities of Caco-2 and Fuji cells transfected with a series of deletion mutants. Data are means ±
s.d. of values from three independent experiments. *P < 0.05. B, Effects of mutation of Ets binding sites in the -98/-25 region of the CD133 P5 on
the transcriptional activity. Left panel, schematic representation of P5-98-based luciferase reporter constructs containing point mutation in two Ets
binding sites (EBS#1 and EBS#2). Open circles represent wild-type sequence (GGAA) and closed circles represent substituted sequence (TTAA).
Right panel, luciferase activities of Caco-2 and Fuji cells transfected with the indicated mutant plasmids. *P < 0.05, **P < 0.01. C, EMSA analysis of
nuclear proteins binding to oligonucleotides containing the Ets binding site of the CD133 P5. The arrowheads a to d indicate specific complexes
of nuclear proteins with GGAA sequence in EBS#2. N.S.: non-specific binding of proteins.
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region containing one proximal Ets motif (EBS#2),
showed two major shifted bands following incubation
with the nuclear extract from Caco-2 (upper panel,
bands a and b), but the EBS1 probe did not. In addition,
these signals were eliminated by the use of mutant
probes (mEBS2) and by competition using ETS consen-
sus oligonucleotides (Cons. EBS) [34], as well as by 50-
fold molar excess amounts of cold wild-type EBS2
probe. -25/-1 oligonucleotides without Ets binding
sequence were not able to affect them. These data indi-
cate that the EBS#2, and not EBS#1, is critical for the
complex formation on the CD133 P5 region. Interest-
ingly, four complexes were obtained using the nuclear
extracts from Fuji under the same conditions (lower
panel, bands a-d), in which complexes a and b appeared
to have similar mobility with those in Caco-2. These
results demonstrated that both tumor cell lines express
any factors that can bind to the EBS in CD133 P5 pro-
moter, although there is a subtle difference in their pre-
ferred binding sequence.
Dominant negative forms of Ets proteins interfere with
CD133 P5 activity
Ets family proteins share a conserved DNA-binding
domain (ETS domain) that recognizes a GGAA
sequence. To determine the implication of Ets factors to
regulate CD133 transcription, the expression levels of 21
human Ets genes were examined by semi-quantitative
RT-PCR (Figure 3A and Additional file 1, Figure S3), in
Caco-2 and Fuji which was separated by the expression
Figure 3 Dominant negative Ets proteins inhibit CD133 P5 activity. A, mRNA expression of ETS1, ETS2, and ELK1 genes in Caco-2 and Fuji
cells. Expression pattern of 21 Ets family genes was analyzed by semi-quantitative RT-PCR analysis, in which Fuji cells with a high level of CD133
expression (CD133high) were enriched by MACS. The expression of the other genes except for ETS1, ETS2, and ELK1 are shown in Additional file
1, Figure S3. B, Transient overexpression of dominant negative Ets2 (Ets2DN) and Elk1 (Elk1DN) in Caco-2 and Fuji cell lines. Cells were
transfected with pCXN2-Flag-Ets2DN and -Elk1DN lacking a transcription activation domain. The expression was evaluated by immunoblot
analysis using anti-Flag antibody. C, Effects of dominant negative Ets2 and Elk1 on P5 promoter activity. P5 reporter plasmids were co-transfected
with dominant negative ETS mutants. Data are means ± s.d. of values from three independent experiments. *P < 0.01 vs. mock-transfected cells.
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amount of CD133 by the MACS system. Ets members
were found to be expressed in both tumor lines, but the
expression of ETS1, ELK3, ER81, ERG, and FLI1 genes
were not detected in Caco-2 cells. Comparing the
CD133high fraction with CD133low in Fuji cells, it was
revealed that ETS1, ETS2, ELF2, ESE1, ELF4, ERG, FLI1,
and FEV genes were highly expressed in the CD133-
expressing population.
To test whether Ets proteins could specifically mediate
P5 transcription, we used a transient transfection
approach, employing dominant-negative Ets2 (Ets2DN)
and Elk1 (Elk1DN) lacking a transactivation domain.
Expression of Ets2DN and Elk1DN resulted in signifi-
cant inhibition of P5 activity in both cell lines (Figure
3B, Figure 3C). Since the use of dominant negative Ets
constructs can broadly interfere with the function of
multiple Ets factors [38], studies utilizing dominant
negative forms of Ets cannot identify which members of
the Ets family are actually important. Therefore, these
results indicate that any Ets factors with ETS domain
are required for P5 activity. In addition, the partial
decrease of P5 activity by EtsDN constructs might
reflect the presence of any redundant factors to achieve
P5 transcription.
MEK/ERK pathway is necessary for CD133 transcription
As several Ets factors, including Ets2 and Elk1, have
been shown to be activated through phosphorylation by
ERK1/2 (also known as p44/42 MAPK), we examined
the contribution of the ERK pathway to CD133 gene
expression. ERK1/2 were constitutively activated without
the external stimuli in both tumor cell lines, and this
phosphorylation of ERK1/2 was diminished by the treat-
ment of U0126 (Figure 4A), a potent and specific inhibi-
tor of MEK1/2, which binds to MEK1 and MEK2
regardless of its activation state to inhibit ERK1/2 phos-
phorylation noncompetitively. Furthermore, to investi-
gate the involvement of MEK/ERK signaling in P5
activity, reporter analysis was performed in the presence
or absence of U0126. Treatment of Fuji cells with
U0126 led to the marked inhibition of P5 activity (Fig-
ure 4B). No cell toxicity was observed concerning mor-
phology and growth of both cell lines under the
conditions of this experiment (data not shown). Consis-
tently, U0126 also markedly decreased the expression of
CD133 protein in Fuji cells (Figure 4C), indicating that
the MEK/ERK signaling is implicated in P5-mediated
CD133 expression. In contrast, the same concentration
of U0126 could not affect P5 activity and expression of
CD133 in Caco-2 cells, suggesting that another pathway
could regulate Ets-mediated P5 transcription in Caco-2
cells. However, it remains possible that the ERK path-
way might simultaneously regulate other promoters (P1
to P4). In fact, ERK inhibition decreased the expression
of exon 1B- and 1D- and 1E-containing CD133 mRNA,
but increase exon 1C-containing one (Additional file 1,
Figure S4). These data indicate cell type-specific regula-
tion of CD133 gene expression by the ERK pathway.
Inhibition of MEK/ERK pathway abolishes side population
in Caco-2 cells
To assure the relevance of the ERK pathway to stem-like
characteristics, the effect of U0126 on the amount of SP
was assessed by flow cytometric analysis. The SP frac-
tion in tumor cells has been known to define the popu-
lation containing stem-like cells, which highly express
ATP-binding cassette (ABC) transporters to efflux both
Hoechst dye and chemotherapeutic agents, and to have
a high capacity to form tumor xenografts in mice [39].
In our experiments, the side population represented
approximately 2% in the Caco-2 cell line (Figure 4D,
Figure 4E). Treatment with verapamil, an inhibitor of
the ABC transporters, completely ablated this popula-
tion. In contrast, no distinct SP was visible in the Fuji
cell line (data not shown). Treatment of Caco-2 with
U0126 dramatically reduced the SP frequency to 0.15%
(Figure 4D, Figure 4E). This result emphasized our con-
clusion that ERK is a key molecule in the signal trans-
duction to maintain stem-like features in tumor cells.
Ets2 increases CD133 mRNA levels in human astrocytes,
but cannot confer tumorigenicity
To examine whether Ets factor could increase CD133
expression and confer tumorigenicity in normal cells, we
established the immortalized human astrocytes overex-
pressing Ets2 (NHA/TSE2). The increase of CD133
mRNA expression was detected in NHA/TSE2 compar-
ing to NHA/TS cells and its effect was strongly
enhanced by the treatment with demethylating agent 5-
Aza-dC and histone deacetyltransferase inhibitor TSA
(Figure 5A). 5Aza-dC/TSA treatment has been shown to
open the chromosomal region to increase accessibility
for transcription factor complexes to assemble at the
promoter and drive gene transcription. However, the
elevated protein level of CD133 could not be detected
by FACS analysis (Additional file 1, Figure S5). Instead,
approximately 0.04% of side population diminished by
verapamil was observed in the NHA/TSE2 cells, whereas
substantial SP was not visible in NHA/TS cells (Addi-
tional file 1, Figure S6). To assess the potential of Ets2
on tumorigenicity, NHA/TSE2 cells were subcuta-
neously implanted into NOD/SCID mice. All positive
control mice implanted with 5 × 106 NHA/TSR cells,
which is a transformed astrocytes [27], developed
tumors at 4-6 weeks with 100% incidence (4/4), whereas
any of the mice injected with NHA/TS or NHA/TSE2
cells could not grew as tumors at least by 6 weeks (0/4)
(Figure 5B). These data indicate that Ets2 is not
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Figure 4 Inhibition of MEK/ERK pathway attenuates CD133 expression and side population frequency. A, Inhibition of endogenous ERK
activation by U0126. Immunoblot analysis was performed with phospho-ERK1/2 and ERK1/2 antibodies. B, Effects of U0126 on P5 promoter
activity. Cells treated with DMSO or U0126 for 24 hours were transfected with P5 reporter plasmid, and incubated for an additional 48 hours in
the presence of U0126. Data are means ± s.d. of values from three independent experiments. *P < 0.05. C, Effect of U0126 on CD133 protein
expression. Caco-2 and Fuji cells were incubated with DMSO or U0126 for 72 hours, and the expression of CD133 protein was analyzed. Actin is
an internal control. D, Effect of U0126 on the side population frequency in Caco-2 cells. Caco-2 cells were incubated with DMSO or U0126 for 72
hours, stained with Hoechst 33342, and subjected to side population analysis. Hoechst dye was excited with the UV laser and its fluorescence
was resolved with a Hoechst blue (y-axis) and Hoechst red (x-axis). Red boxes are defined as SP fractions with low intensity of Hoechst staining.
F. Bar graph representation of the percentages of side population cells in Caco-2 cells. Data are expressed as the means ± s.d. for three
independent experiments. *P < 0.01.
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Figure 5 Ras-transformed astrocytes have an ability to form neurosphere-like colonies with the increased expression of CD133 mRNA.
A, Expression of CD133 mRNA in NHA/TSE2 and NHA/TSR cells. The expression levels of CD133 mRNA were examined by semi-quantitative RT-
PCR analysis. The number of PCR cycle was 32 for CD133. GAPDH is an internal control. 5Aza-dC; 5-Aza-2-deoxycitidine. TSA; Trichostatine A. B, In
vivo tumor formation analysis. 5 × 106 of each cells were subcutaneously injected into NOD/SCID mice. Tumor formation was evaluated after 6
weeks of inoculation. The number of mice developing tumors/numbers of mice injected is shown. C, Representative images of NHA/TS and
NHA/TSR cells cultured in neural stem cell medium. Bar graph shows mean ± s.d. of the absolute number of primary and secondary TSR spheres,
which was measured from three independent experiments. Cell clusters ≥ 50 μm in diameter were counted as spheres. Secondary sphere assay
was also performed at the same condition. Scale bar = 200 μm. D, Representative images of a sphere derived from single NHA/TSR cell. FACS-
purified single NHA/TSR cell was cultured in NSC medium in a 48-well plate for 2 weeks. E, Individual TSR-derived clonal sphere was dissociated
and reseeded in NSC medium (left) and in 10%FBS-DMEM (right) to confirm the secondary sphere formation activity and differentiation
potential, respectively. Scale bar = 200 μm.
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sufficient to fully transform normal human astrocytes,
and thus the acquisition of tumor stem-like characters
may be accomplished by synergistic actions of multiple
factors.
Human astrocytes transformed by oncogenic Ras can
form neurosphere-like colonies with the increased
expression of CD133 mRNA
NHA/TSR cells form malignant tumors with features of
human anaplastic astrocytoma, the WHO classification
Grade III in mice [27] and malignant astrocytoma has
been well-known to display a stem cell signature [2]. To
confirm whether Ras-mediated transformation in human
astrocytes could confer stem-like features in parallel
with the acquisition of tumorigenicity, we examined the
expression level of CD133 and the activity of neuro-
sphere formation in NHA/TSR cells. In the absence of
5Aza-dC/TSA, the more substantial level of CD133
mRNA was detected in NHA/TSR cells comparing to
NHA/TSE2 cells (Figure 5A), suggesting that Ras might
play an additional role to modulate chromatin structure
of CD133 promoter region. Actually, CD133 expression
is regulated by promoter DNA methylation [24]. How-
ever, the protein level of CD133 could not be increased
(Additional file 1, Figures S5 and S7), suggesting that
Ras activation is also not sufficient to completely restore
CD133 expression in human astrocytes. The generation
of neurospheres is considered as an important symbol
of in vitro neural stem cell culture, as well as an exhibi-
tion of self-renewal capacity [40]. After culturing in
NSC medium containing bFGF and EGF for 2 weeks,
NHA/TSR cells generated significantly greater neuro-
sphere-like colonies (diameter is ≥ 50 μm) than NHA/
TS cells, and this capacity was maintained to generate
secondary neurospheres (Figure 5C). To except the pos-
sibility of cellular aggregates, single NHA/TSR cell was
also sorted using flow cytometry and deposited into 48-
well plates containing NSC medium. NHA/TSR had a
forming efficiency of 12.7 ± 1.5 (26.4%) single spheres
per 48-well plate, as opposed to zero for NHA/TS (Fig-
ure 5D). A single sphere could also maintain the capa-
city to form secondary spheres, as well as differentiate
into adherent cells morphologically identical to original
NHA/TSR cells in 10% FBS-containing medium (Figure
5E), indicating that constitutive activation of the Ras
pathway can trigger the development of stem-like popu-
lation with self-renewing ability to retain stemness, and
possibly that human astrocytes could dedifferentiate to
premature state following to the Ras-mediated transfor-
mation and/or its sequential combination with immorta-
lization. Side population size was not increased in
NHA/TSR cells (Additional file 1, Figure S6). These
results indicate that the expression of CD133 protein
and appearance of side population are not necessarily
required for other tumor stem-like behaviors, at least
for the capacity to form neurospheres in vitro and
tumors in vivo. Finally, NHA/TS cells retrovirally over-
expressed CD133 gene (NHA/TSC) could form a larger
number of colonies comparing to NHA/TS cells in soft-
agar colony formation assay (Additional file 1, Figure
S7). However, their number and size are much less than
those of NHA/TSR even after they were cultured for 3
weeks. In addition, mice subcutaneously implanted with
5 × 106 NHA/TSC cells could not develop any tumors
at least by 6 weeks (Figure 5B), supporting the view that
CD133 is just a concomitant marker for tumorigenic
process.
Discussion
Traditionally, therapeutic procedures for human cancer
have been performed based on the implicit understand-
ing that the tumor population is homogeneous. How-
ever, emerging evidence has suggested that tumors are
hierarchically organized and the capacity of tumor pro-
pagation depends mainly on a sub-population of stem-
like cells. The discovery of stem-like cells in solid
tumors convincingly accounts for chemoresistance, and
recurrence arose in a number of human cancers. Many
studies have been carried out using stem-like population
enriched by a stem cell marker CD133, and these have
demonstrated an increased resistance of CD133+ stem-
like tumor cells to treatment with chemotherapeutic
agents compared with CD133- tumor progenies. In addi-
tion, the side population has been also used as one of
the methods to enrich the stem-like tumor cells, as well
as normal stem cells, and is defined by Hoechst dye
exclusion property. Although it remains to be clarified
whether the expression of CD133 and transporter mole-
cules directly contribute to tumor progression, the regu-
latory mechanism of stem-related gene expression could
help our understanding of tumor stemness and should
be investigated further to improve the development of
eradicative therapies against human malignancies.
Previously, we and other investigators reported that
the expression levels of CD133 mRNA are positively
correlated with tumor stage and the poor prognosis of
patients [24,41-47]. However, it is still controversial
whether CD133 is just a concomitant marker for
tumorigenic process or whether it directly leads to
tumorigenesis. To examine the role of CD133 expres-
sion in normal cells, we established NHA/TSC cells and
found that overexpression of CD133 is not sufficient to
induce tumorigenic transformation in vivo (Figure 5B
and Additional file 1, Figure S7). Interestingly, a recent
study using genetically engineered mice suggested that
CD133 is just a concomitant marker of stem-like cells.
Tumors had developed throughout the entire intestine
when Wnt signaling was selectively activated in CD133+
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or Lgr5+ adult small intestinal stem cells [21,48]. In con-
trast, carcinomas with lower malignancy were found in
less than one in five mice when the same system was
targeted to non-stem cells [48]. Therefore, it is concei-
vable that malignant expansion of tumors depends on
the latent potential of adult stem cells to proliferate or
differentiate, and thus the increase of CD133 mRNA in
a higher stage of tumors might be a result of unregu-
lated expansion of CD133+ stem-like cells. Considering
that NHA/TSR cells possess the high activity to form
neurospheres and tumors in mice without entire expres-
sion of CD133 protein (Figure 5), these data would sup-
port the view that CD133 is just a marker of stem-like
cells.
The expression mechanisms of CD133 gene have not
been examined so far, despite its expression being
recognized as an important stem-related biomarker for a
number of different cell lineages, probably because
CD133-expressing cells are a very rare sub-population
for transcriptional analysis. In addition, we observed
some culture effects, in that serial passages of primary
glioblastoma culture easily diminished CD133 expres-
sion (data not shown). The two tumor cell lines used in
this study stably preserve a high proportion of CD133
+-proliferating cells, and they could be useful tools to
further investigate the expression machinery for CD133.
In Figure 1D, we have shown that P5 promoter exhi-
bits the highest activity among the five alternative pro-
moters, but it should be noted that P5 does not
necessarily predominate the CD133 expression. First,
the stability and translational efficiency of CD133
mRNA might be varied by 5’-UTR sequences containing
exon1s (1A, 1B, 1C, 1D, or 1E). Indeed, the modulation
of 5’-UTR involves in the regulated expression of some
proteins regulating growth and differentiation of normal
stem cells and plays a role in the progression of specific
types of cancers, such as leukemia and prostate cancer
[49]. Therefore, the role of each exon1 on CD133
expression needs to be determined. Experiments should
be limited to the use of the whole locus including all of
exon1s for reporter assay.
Second, epigenetic modifications such as DNA methy-
lation and histone modification have been reported to
play important roles in the regulation of various genes
[50]. However, it is questionable that the physiological
status of chromatin complexes is accurately reconsti-
tuted in the transient reporter assay system. Indeed, we
reported that the expression levels of CD133 mRNA
were dramatically restored by the treatment of glioma
cell lines with the demethylating agent 5-azacytidine
and/or histone deacetylase inhibitor valproic acid [24].
Therefore, it might be possible that epigenetic modifica-
tion is the final determinant of CD133 gene expression
and stem-like features. Further studies are needed to
address the molecular mechanisms to epigenetically
maintain the active state of CD133 gene, containing
demethylases of DNAs and/or acethyltransferases of
histones.
The Ras/ERK pathway plays a crucial role in transdu-
cing signals from various external stimuli to control cell
adhesion, proliferation, migration, and survival. It is
well-known to be deregulated in some types of human
tumors [51]; Ras mutations are found in 45% of colon
carcinomas and 90% of pancreatic cancers; Raf muta-
tions are found in two-thirds of melanomas, where
TSLCs have been enriched by sorting for CD133 protein
expression. The Ras pathway was also reported to be
involved in stem cell regulation. Undifferentiated human
embryonic stem cells (hESCs) require a growth factor
FGF, which transmits signals mainly by the Ras/ERK
pathway [52]. Indeed, ERK is active in undifferentiated
hESCs and inhibition of the ERK pathway with U0126
caused extensive cell death and differentiation [53].
It is noteworthy that myeloproliferative disorders
could be initiated by K-Ras(G12D) in a highly restricted
population enriched for hematopoietic stem cells
(HSCs) [54]. The expression of activated M-Ras in
HSCs initiated leukemogenic transformation [55]. In
addition, sophisticated mouse tumor models triggered
by oncogenic Ras have demonstrated the contribution of
the Ras/ERK pathway to the acquisition of cancer stem
cell properties, in primary human mammary epithelial
cells (HMECs) [56]. H-RasV12 also causes the p53-
knockout mouse-derived astrocytes to be transformed
into brain tumor stem-like cells, in which MEK/ERK
pathway is responsible for neurosphere formation [57].
Interestingly, let-7 microRNA, known to downregulate
Ras, reduces proliferation, sphere formation, and the
proportion of undifferentiated cells in vitro and tumor
formation and metastasis in vivo [58]. These reports
support that the Ras/ERK pathway plays a central role
to acquire and maintain tumor stem-like properties.
Furthermore, we have shown that ERK inhibition
diminishes the frequency of the side population, but we
could not reveal the detailed mechanisms. RT-PCR ana-
lysis revealed that the expression of ABCC1 mRNA was
decreased by U0126 treatment, while that of ABCG2
mRNA was increased in Caco-2 cells (data not shown).
Although it has not been elucidated which transporters
have a dominant role for SP phenotype in Caco-2 cells,
the ERK pathway might regulate multiple events at the
upstream of the SP phenotype, including gene transcrip-
tion and protein stabilization. Actually, it has been
reported that inhibition of the Ras/ERK pathway also
promotes ABCB1 protein degradation to diminish the
cellular multidrug resistance in the human colorectal
cancer cell lines [59]. SP cells are also known to repro-
duce NSP cells [35]. Therefore, U0126 might affect the
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division patterns of SP cells via the decrease of self-
renewal and/or the increase of differentiation. In the
future, we will clarify these points, and should examine
whether the therapeutic approaches to Ras/ERK inhibi-
tion could be effective for eradication of stem-like cells
in tumor mass.
In this study, we found that the Ras/ERK pathway is
implicated in at least one of the stem-like characteristics
in all of the examined tumor cell lines: SP size in Caco-
2, CD133 expression in Fuji, and sphere and tumor
forming activity in NHA/TSR cells. These finding sug-
gest that Ras/ERK could be a common upstream path-
way to govern the entirety of downstream
characteristics. However, the contribution of Ras/ERK
was varied in a cell type-specific manner; Ras/ERK does
not contribute to CD133 protein expression in Caco-2
and NHA/TSR, and SP appearance in Fuji and NHS/
TSR cells. Crosstalk between ERK and other pathway
specific to an individual type of tumors may result in
the diversity of stem-like hallmarks.
Conclusions
This study has characterized the critical cis-acting ele-
ment in CD133 promoter P5 and identified one poten-
tial pathway required for CD133 gene regulation, side
population maintenance, and spheres forming activity in
stem cell culture. As CD133 expression is now recog-
nized as one of the most important biomarkers for the
enrichment of stem-like tumor cells, the Ets motifs and
Ras/ERK pathway we identified in this study could lead
to a more comprehensive understanding of the molecu-
lar basis of tumor stemness. Further characterization of
the five CD133 promoters, including protein-protein
interactions and epigenetic regulations, must allow us to
identify bona fide targets that define tumor stemness,
and facilitate the development of TSLC-targeted thera-
pies to eradicate human malignancies.
Additional file 1: Additional Figures. Figures S1-7 as referred to in the
main text.
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